News

Filter

Current filters:

solanezumab

1 to 9 of 10 results

Shire settles with Actavis/Watson over Intuniv; Lilly sues J&J

26-04-2013

Ireland-headquartered Shire (LSE: SHP) says it has settled all pending litigation with Actavis (NYSE:…

ActavisEli LillyGenericsIntunivJohnson & JohnsonNeurologicalNorth AmericaPatentsPharmaceuticalShiresolanezumabWatson Pharmaceuticals

Lilly plans new trial of Alzheimer's hope solanezumab

13-12-2012

US drug major Eli Lilly (NYSE: LLY) is planning to carry out an additional Phase III trial of its Alzheimer's…

Eli LillyNeurologicalPharmaceuticalResearchsolanezumab

Another Alzheimer's drug hits the dust as Bristol-Myers drops avagacestat development

04-12-2012

In yet another research disappointment, US drug major Bristol-Myers Squibb (NYSE: BMY) recently assessed…

avagacestatbapineuzumabBristol-Myers SquibbMK-8931NeurologicalPharmaceuticalResearchsolanezumab

Roche and Lilly drugs chosen for major Washington University Alzheimer's prevention trial

11-10-2012

Leading scientists at the USA's Washington University at St Louis have selected the first drugs to be…

BiotechnologyEli LillygantenerumabNeurologicalPharmaceuticalResearchRochesolanezumab

Mixed results with Eli Lilly Alzheimer's drug solanezumab, but investors pleased

09-10-2012

US pharma major Eli Lilly (NYSE: LLY) yesterday reported detailed results from two Phase III studies…

BiotechnologyEli LillyNeurologicalPharmaceuticalResearchsolanezumab

Mixed news on Lilly's Alzheimer's drug solanezumab; Alimta patent upheld

28-08-2012

US drug major Eli Lilly (NYSE: LLY) revealed last Friday that the primary endpoints, both cognitive and…

AlimtaEli LillyLegalNeurologicalNorth AmericaOncologyPatentsPharmaceuticalResearchsolanezumabTeva Pharmaceutical Industries

Alzheimer’s drug market to triple to $14.3 billion by 2020, says DR

09-10-2011

The Alzheimer’s disease drug market will nearly triple over the next 10 years, increasing from $5.4…

bapineuzumabEli LillyGlobalJohnson & JohnsonMarkets & MarketingNeurologicalPfizerPharmaceuticalsolanezumab

1 to 9 of 10 results

COMPANY SPOTLIGHT

Menarini

Back to top